INBX
Inhibrx Biosciences, Inc.
99.60$
-0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| -271.6% | -223.5% | -268.7% | -352.8% | -374.5% | -1,127.3% | -5,260.1% | -10,739.4% | -97,204.5% | -9,984.2% | |
| 3.8% | 4.8% | 7.9% | 12.8% | 8.0% | 16.8% | 55.9% | 66.2% | 1,142.5% | 191.0% | |
| 8.3% | 14.1% | 28.9% | 43.7% | 39.2% | 211.2% | 932.9% | 1,380.3% | 29,259.0% | 856.8% | |
| -94.2% | 11.9% | 49.4% | 38.3% | 99.1% | -245.8% | 144.3% | 852.7% | 26,025.5% | -585.7% | |
| 3.2% | 16.0% | 16.6% | 19.9% | 10.6% | 12.1% | 31.3% | 255.2% | 1,298.5% | 2.4% | |
| -3.2% | -16.0% | -16.6% | -19.9% | -10.6% | -11.4% | -31.3% | -255.2% | -1,298.5% | -2.2% | |
| – | 16.4% | 9.6% | – | – | – | – | – | – | – | |
| – | – | – | – | – | -4.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | 0.0% | 7,689.6% | |
| 431.5% | 161.3% | 153.0% | 476.5% | 1,299.6% | 1,175.7% | 11,795.2% | 11,220.1% | 35,839.0% | 7,803.5% | |
| 156.7% | -78.1% | -132.3% | 103.8% | 914.5% | 37.0% | 6,503.8% | 225.5% | -62,664.0% | -2,182.8% | |
| -274.8% | -239.4% | -285.3% | -372.7% | -385.2% | -1,139.5% | -5,291.4% | -10,994.6% | -98,503.0% | -9,986.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.